Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440987 | 0.88 | HSD17B3 (0.44) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16441004 | 0.86 | KDM4E (0.46) | RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10066188 | 0.84 | KDM4E (0.55) | RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16441005 | 0.81 | LMNA (0.44) | RAB9AATMMAPK1MAPTNPC1 | |
| SCHEMBL14745543 | 0.78 | SIGMAR1 (0.34) | SIGMAR1RAB9AATMMAPK1MAPT | |
| SCHEMBL10857824 | 0.78 | BRPF1 (0.53) | SIGMAR1RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16440999 | 0.78 | HSD17B3 (0.42) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16441006 | 0.77 | RAB9A (0.39) | RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27594512 | 0.74 | TUBB4A (0.52) | SIGMAR1RAB9AATMNPC1ALDH1A1 | |
| SCHEMBL21573033 | 0.73 | ALDH1A1 (0.59) | SIGMAR1RAB9AATMMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | SIGMAR1 868/4885RAB9A 1346/4885ATM 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.